These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
668 related articles for article (PubMed ID: 19733829)
1. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines. Tetteh E Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829 [No Abstract] [Full Text] [Related]
2. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. 't Hoen E Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298 [No Abstract] [Full Text] [Related]
3. Access to medicines in Senegal: results of a sample survey. Garenne M; Candau D; Guimier JM; Badiane M; Diop AC; Teulières LC Trop Doct; 2006 Jan; 36(1):5-8. PubMed ID: 16483417 [TBL] [Abstract][Full Text] [Related]
4. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa. Buckely M Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760 [No Abstract] [Full Text] [Related]
5. Pharmacy benefit managers and their obligations during serious prescription drug shortages. Teagarden JR; Epstein RS Clin Pharmacol Ther; 2013 Feb; 93(2):143-5. PubMed ID: 23337523 [TBL] [Abstract][Full Text] [Related]
6. Supporting the production of pharmaceuticals in Africa. Dong J; Mirza Z Bull World Health Organ; 2016 Jan; 94(1):71-2. PubMed ID: 26769999 [No Abstract] [Full Text] [Related]
7. Providing affordable essential medicines to African households: the missing policies and institutions for price containment. Tetteh Ek Soc Sci Med; 2008 Feb; 66(3):569-81. PubMed ID: 18023953 [TBL] [Abstract][Full Text] [Related]
8. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain. James JS AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151 [TBL] [Abstract][Full Text] [Related]
9. Access to medicines report cards. Mullard A Nat Rev Drug Discov; 2016 Nov; 15(12):811. PubMed ID: 27895336 [No Abstract] [Full Text] [Related]
10. [Quality of medicines in least developed countries]. Videau JY Med Trop (Mars); 2006 Dec; 66(6):533-7. PubMed ID: 17286015 [TBL] [Abstract][Full Text] [Related]
11. The Health Impact Fund: incentives for improving access to medicines. Banerjee A; Hollis A; Pogge T Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894 [No Abstract] [Full Text] [Related]
12. The cost of prescription drugs: rising concerns over equity, fairness and access to essential care. Work DR; Domino ME N C Med J; 2003; 64(6):270-4. PubMed ID: 14983614 [No Abstract] [Full Text] [Related]
13. Anti-Glaxo campaign heats up in United States. Moynihan R BMJ; 2003 Feb; 326(7386):413. PubMed ID: 12595358 [No Abstract] [Full Text] [Related]
14. Access to medicines and global health: will Canada lead or flounder? Orbinski J CMAJ; 2004 Jan; 170(2):224-6. PubMed ID: 14734437 [No Abstract] [Full Text] [Related]
15. Re-examining 'professionalism' in pharmacy: a South African perspective. Williams KF Soc Sci Med; 2007 Mar; 64(6):1285-96. PubMed ID: 17161511 [TBL] [Abstract][Full Text] [Related]
16. Financing and Distribution of Pharmaceuticals in the United States. Dabora MC; Turaga N; Schulman KA JAMA; 2017 Jul; 318(1):21-22. PubMed ID: 28505252 [No Abstract] [Full Text] [Related]
17. Maintaining drug supply to Greece in an uncertain future. Burki TK Lancet Oncol; 2015 Aug; 16(8):e382. PubMed ID: 26166437 [No Abstract] [Full Text] [Related]
18. Pharmaceutical industry and payer partnerships to manage costs and improve quality. Mauch RP Manag Care; 2001 Sep; 10(9 Suppl):2-4; discussion 9-12. PubMed ID: 11729438 [No Abstract] [Full Text] [Related]
20. Access to medicines is not the business of the pharma industry. Brown PJ J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):9-11; discussion 12-4. PubMed ID: 12942664 [No Abstract] [Full Text] [Related] [Next] [New Search]